Qiagen seen down after 'mixed bag' amid CEO departure, Q3 results beat

Qiagen NV

05/11/2025 07:58

** Netherlands-based biotechnology company Qiagen  QIA.DE seen down 3.5% after announced "a mixed bag of news" on Tuesday, Deutsche Bank says, as the company reported its CEO's departure, a Q3 results beat, a guidance adjustment, a share buyback and an acquisition

** The company announced its CEO Thierry Bernard will step down after a successor is appointed, as well as a marginal trim to adjusted EBIT outlook for 2025 and a softer sales exit rate

** The company's solid Q3 results are not enough to balance the negatives, Deutsche Bank analysts say, while analysts at J.P.Morgan point to revenue, net sales, CER growth and adjusted EPS all above analysts' expectations according to a Vara consensus

** Qiagen also reiterated 2025 guidance for net sales growth and CER growth and raised its guidance for adjusted EPS

** The company also announced it would acquire Parse Biosciences in a $225 mln cash deal with $55 mln in milestone payments contingent on meeting targets over the next few years, and a $500 mln synthetic share repurchase programme, expected to be completed on or about 7 January 2026

** Up to the previous session's close, shares were down 7.8%​ YTD

 (Reporting by Bernadette Hogg)

 ((bernadette.hogg@thomsonreuters.com))